BAP1 Loss of Function
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma (NCT02860286) | Epizyme, Inc. | 2016-07-01 |
Track BAP1 Loss of Function automatically
Every clearance here is in the API, with alerts when new ones post.